Masataka Katashima

647 total citations
46 papers, 513 citations indexed

About

Masataka Katashima is a scholar working on Molecular Biology, Epidemiology and Pharmacology. According to data from OpenAlex, Masataka Katashima has authored 46 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Epidemiology and 7 papers in Pharmacology. Recurrent topics in Masataka Katashima's work include Pharmacogenetics and Drug Metabolism (5 papers), Antifungal resistance and susceptibility (5 papers) and Herpesvirus Infections and Treatments (5 papers). Masataka Katashima is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Antifungal resistance and susceptibility (5 papers) and Herpesvirus Infections and Treatments (5 papers). Masataka Katashima collaborates with scholars based in Japan, United States and Netherlands. Masataka Katashima's co-authors include Yasufumi Sawada, Tatsuji Iga, Akio Kawamura, Taiji Sawamoto, Kenji Tabata, Koujirou Yamamoto, Yoji Tokuma, Yusuke Tanigawara, Kazuyoshi Yamamoto and Atsunori Kaibara and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Masataka Katashima

46 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masataka Katashima Japan 13 119 108 104 104 89 46 513
Atsunori Kaibara Japan 9 144 1.2× 70 0.6× 42 0.4× 162 1.6× 58 0.7× 21 513
E. Musch Germany 14 130 1.1× 127 1.2× 84 0.8× 85 0.8× 152 1.7× 44 623
Takahiro Shibayama Japan 12 56 0.5× 104 1.0× 27 0.3× 63 0.6× 135 1.5× 37 437
Chan‐Loi Yong United States 13 400 3.4× 162 1.5× 37 0.4× 260 2.5× 88 1.0× 22 944
Haisheng You China 14 59 0.5× 220 2.0× 48 0.5× 75 0.7× 139 1.6× 42 606
Karen May Germany 14 67 0.6× 176 1.6× 57 0.5× 60 0.6× 478 5.4× 25 921
Amanda Freeman United States 11 72 0.6× 177 1.6× 80 0.8× 95 0.9× 287 3.2× 13 748
Gunilla Englund Sweden 6 44 0.4× 109 1.0× 124 1.2× 66 0.6× 436 4.9× 6 608
Christian Zimmermann Germany 14 51 0.4× 118 1.1× 93 0.9× 41 0.4× 322 3.6× 21 622
Yasuro KAWAGUCHI Japan 14 53 0.4× 202 1.9× 195 1.9× 37 0.4× 282 3.2× 44 627

Countries citing papers authored by Masataka Katashima

Since Specialization
Citations

This map shows the geographic impact of Masataka Katashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masataka Katashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masataka Katashima more than expected).

Fields of papers citing papers by Masataka Katashima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masataka Katashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masataka Katashima. The network helps show where Masataka Katashima may publish in the future.

Co-authorship network of co-authors of Masataka Katashima

This figure shows the co-authorship network connecting the top 25 collaborators of Masataka Katashima. A scholar is included among the top collaborators of Masataka Katashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masataka Katashima. Masataka Katashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Nomura, Yuki, et al.. (2020). Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression. Clinical Therapeutics. 42(6). 1067–1076.e2. 2 indexed citations
4.
Keirns, James J., et al.. (2017). Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. Advances in Therapy. 34(12). 2625–2637. 20 indexed citations
5.
García-Hernández, Alberto, et al.. (2017). Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults. Advances in Therapy. 34(11). 2466–2480. 9 indexed citations
6.
Kowalski, Donna, Kota Kato, Masataka Katashima, et al.. (2017). The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies. Advances in Therapy. 34(12). 2612–2624. 10 indexed citations
7.
Nomura, Yuki, Junko Toyoshima, Atsunori Kaibara, et al.. (2016). Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females. Drug Metabolism and Pharmacokinetics. 31(6). 411–416. 8 indexed citations
8.
Katashima, Masataka, Atsunori Kaibara, Koji Chono, et al.. (2016). Integrative pharmacokinetic–pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes. Drug Metabolism and Pharmacokinetics. 31(4). 323–332. 2 indexed citations
9.
Minoura, Hideaki, et al.. (2015). Pharmacological and clinical profile of nitisinone (Orfadin<sup>®</sup> Capsules): a therapeutic agent for hereditary tyrosinemia type 1. Folia Pharmacologica Japonica. 146(6). 342–348. 1 indexed citations
10.
Gelderen, Marcel van, et al.. (2015). Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Clinical Therapeutics. 37(5). 1031–1044. 18 indexed citations
11.
Matsushima, Hiroshi, Masataka Katashima, Taiji Sawamoto, et al.. (2013). Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies. Clinical Drug Investigation. 34(1). 27–35. 22 indexed citations
12.
13.
Tabata, Kenji, Masataka Katashima, Akio Kawamura, Atsunori Kaibara, & Yusuke Tanigawara. (2006). Population Pharmacokinetic Analysis of Micafungin in Japanese Patients with Fungal Infections. Drug Metabolism and Pharmacokinetics. 21(4). 324–331. 23 indexed citations
14.
Tabata, Kenji, Masataka Katashima, Akio Kawamura, Akira Kagayama, & Shigeru Kohno. (2006). Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis. European Journal of Drug Metabolism and Pharmacokinetics. 31(2). 123–128. 11 indexed citations
15.
Katashima, Masataka, et al.. (2002). Distribution and excretion after intravenous dosing of [^ C] micafungin to rats. 50. 80–87. 4 indexed citations
16.
Katashima, Masataka, Yasuhiko Yamada, Koujirou Yamamoto, et al.. (1999). Analysis of Antiplatelet Effect of Ticlopidine In Humans: Modeling Based on Irreversible Inhibition of Platelet Precursors in Bone Marrow. Journal of Pharmacokinetics and Biopharmaceutics. 27(3). 283–296. 5 indexed citations
17.
Koizumi, Fumiaki, et al.. (1999). Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK706. Clinical Pharmacology & Therapeutics. 66(5). 501–508. 3 indexed citations
18.
Katashima, Masataka, T Irino, Akio Kawamura, et al.. (1998). Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5α-reductase, in healthy volunteers. Clinical Pharmacology & Therapeutics. 63(3). 354–366. 8 indexed citations
19.
Ito, Kiyomi, Toshimitsu Momose, Hajime Kotaki, et al.. (1997). Pharmacokinetic Analysis of Benzodiazepine Receptor Binding of [123I]Iomazenil in Human Brain. Pharmaceutical Research. 14(8). 999–1003. 1 indexed citations
20.
Yamamoto, Koujirou, et al.. (1996). Parmacodynamic Analysis of Antiplatelet Effect of Aspirin in the Literature. Modeling Based on Inhibition of Cyclooxygenase in the Platelet and the Vessel Wall Endothelium.. Japanese Journal of Hospital Pharmacy. 22(2). 133–141. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsunori Kaibara Breakdown of academic impact, for papers by E. Musch Breakdown of academic impact, for papers by Takahiro Shibayama Breakdown of academic impact, for papers by Chan‐Loi Yong Breakdown of academic impact, for papers by Haisheng You Breakdown of academic impact, for papers by Karen May Breakdown of academic impact, for papers by Amanda Freeman Breakdown of academic impact, for papers by Gunilla Englund Breakdown of academic impact, for papers by Christian Zimmermann Breakdown of academic impact, for papers by Yasuro KAWAGUCHI
Rankless by CCL
2026